Over the last 20 years, the growth of biotherapeutic antibodies, has had a dramatic impact on many areas of medicine, including infectious, immune-mediated, and respiratory diseases, as well as hematology and oncology. APBio is currently developing fully-human，mono- and bi-specific antibodies with novel mechanisms of action to fulfill unmet medical needs.
Combining our integrated protein engineering and antibody technology, we have produced a portfolio of biotherapeutic leads & bi-specific antibodies to treat serious medical conditions with a primary clinical focus on oncology. With mechanism-based drug design focusing on disease-specific targets, we are aiming to provide patients with medicines that are safe, efficacious and cost-effective. We believe that the biotherapeutics developed this way will offer important clinical and economic advantages, making these protein drugs better choices for the patients.
Client-initiated antibody discovery projects
Collaboration
Out-licensing
We have currently generated several bi-specific antibodies, and established partnership with other companies for further development for some of them, including IBI302 currently in PI studies.
We’ll continue expanding our antibody products in oncology and immunology for in-house pipeline and development partners. In the meantime, we are also looking for collaboration on innovative targets, as well as promising antibodies for bi-specific development.
Mr. Chen is currently serving as Vice General Manager, Investment Management and Special Assistant to Chairman of Ruentex Group.
He obtained his Master’s degree in Business Administration from National Taiwan University.
Ms. Audrey is Honorary Deputy Chairman of PwC Taiwan, Adjunct Professor of National Chengchi University, Advisor of BioTReC of Academia Sinica and Advisor of Ministry of Health and Welfare.
Ms. Audrey holds a Master of Business Administration, Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce, Department of Accounting, National Chengchi University.
With over 35 years of experience as a Taiwan-licensed CPA, she has successfully assisted many biopharma and medtech companies to list in Taiwan. Audrey also has extensive overseas IPO advisory experiences.
Dr. Jeng Her is the founder and CEO of AP Biosciences. He had received a bachelor’s degree in Physics from the National Taiwan University, then turned into biology and earned a Ph.D. degree in Microbiology and Immunology from the University of Virginia in 1993.
Before setting up AP Biosciences in Taiwan, he had co-founded KaloBios Pharmaceuticals in the Silicon Valley soon after his post-doctoral training at Bristol-Myers Squibb and DNAX Research Institute (now part of Merck). At KaloBios, he co-invented the antibody Humaneering™, a technology which converts non-human antibodies into engineered human-like antibodies with sequences close to the germline to minimize immunogenicity. The technology was then licensed to Novartis non-exclusively for $32M. In 2013, KaloBios went public on NASDAQ with three antibodies in clinical trials, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $270 million.
Ms.Ivy is currently serving of Pau Jar Group.
Ms.Ivy has a B.S. degree in Department of Nursing from Chang Jung Christian University.
Dr. Lai has more than 23 years of experience in drug discovery. As Senior Principal Scientist at Merck & Co., Dr. Lai led and directed multiple independent project teams to develop potential clinical candidates. He also acted as a core team member of early development and product development in several clinical studies.
During his tenure at Merck, the teams have identified more than 10 preclinical candidates. Several of them are currently in clinical trials. He also received several awards from Merck, Merck Divisional/Staff Area Award in 2007, Special achievement award in 2009, and Merck Research Laboratories Pipeline Award in 2018. The crowning achievements of his career at Merck comes with the approval of an antiviral drug by FDA in 2018.
Dr. Lai has had over 69 papers published in peer-reviewed journals. Dr. Lai did post-doctoral study in at Massachusetts Institute of Technology, earned his Ph.D. in Bio-Organic Chemistry from University of Minnesota.
Dr. Jeng Her is the founder and CEO of AP Biosciences. He had received a bachelor’s degree in Physics from the National Taiwan University, then turned into biology and earned a Ph.D. degree in Microbiology and Immunology from the University of Virginia in 1993.
Before setting up AP Biosciences in Taiwan, he had co-founded KaloBios Pharmaceuticals in the Silicon Valley soon after his post-doctoral training at Bristol-Myers Squibb and DNAX Research Institute (now part of Merck). At KaloBios, he co-invented the antibody Humaneering™, a technology which converts non-human antibodies into engineered human-like antibodies with sequences close to the germline to minimize immunogenicity. The technology was then licensed to Novartis non-exclusively for $32M. In 2013, KaloBios went public on NASDAQ with three antibodies in clinical trials, including KB001 for ventilator-associated pneumonia, which was licensed to Sanofi-Pasteur for $270 million.
Dr. Jon-Jih Liao received his M.D. degree from the National Taiwan University in 1990 and completed a residency in family medicine at the National Taiwan University Hospital in 1995. In 1999, he founded the Department of Family Medicine at the New Taipei City Hospital.
In July 2005, Dr. Liao changed his career path and became a Medical Reviewer in the Office of Clinical Science, Center for Drug Evaluation, Taiwan, and subsequently the Team Leader of the IND Review Team in December 2006.
After decades of clinical practice and public services, he had decided to join private sector and became a Medical Advisor for Bristol-Myers Squibb and Eli Lilly in the fields of oncology and diabetology, then a Medical Director at OBI Pharma responsible for early stage clinical development of OBI-888 before joining AP Biosciences.
Dr. You received his Ph.D. degree on Molecule Medicine from the National Taiwan University, then extended his research in antibody engineering for functionality and stability at the Genomic Research Center, Academia Sinica before joining AP Biosciences.
In 2013, he joined APBio as the first employee of the company, leading the effort on generation of the human antibody phage display library, Omni-Mab, as well as development of cell-based assay platform for screening & isolation of functional antibodies for immunotherapy. One major task under his scientific and technical leadership is to take antibody discovery through IND-enabling studies for selection of lead candidates into clinical development. In the meantime, he was also responsible for the application and execution of two SBIR (Small Business Innovation Research) grants for development of anti-inflammation biologics.
Master of Accounting, Georgia State University.
Former Manager of Provision Co.
MBA of Takming University of Science and Technology.
Former Manager of Fiberpure Co.